实用肿瘤杂志2026，Vol.41Issue(3)：220-225,6.DOI:10.13267/j.cnki.syzlzz.2026.031
从TRIPLETE研究再看左半RAS/BRAF野生型转移性结直肠癌一线治疗的强化策略
Revisiting first-line treatment intensification for left-sided RAS/BRAF wild-type metastatic colorectal cancer in light of TRIPLETE study
程怡 1吴泽华 1骆玉婷 1胡华斌 1张剑威 1邓艳红1
作者信息
- 1. 中山大学附属第六医院肿瘤科,广州市黄埔区中六生物医学创新研究院,广东 广州 510655
- 折叠
摘要
Abstract
The phase Ⅲ TRIPLETE trial compared the triplet regimen modified FOLFOXIRI versus the doublet regimen mFOLFOX6,both combined with an anti-epidermal growth factor receptor(EGFR)antibody,as a first-line treatment for patients with rat sarcoma viral oncogene homolog(RAS)/B-Raf proto oncogene serine/threonine protein kinase(BRAF)wild-type metastatic colorectal cancer(mCRC).The results demonstrated a significant 7.8-month improvement in overall survival(OS)for patients receiving the triplet regimen,providing high-level evidence of a survival benefit for combining triplet chemotherapy with anti-EGFR therapy.This article analyzes the potential reasons for the observed discordance between the OS benefit and objective response rate(ORR)results in the TRIPLETE study.Further-more,it discusses key implementation considerations and optimization strategies for combining anti-EGFR monoclonal antibodies with triplet chemotherapy regimens in clinical practice for advanced malignancies,with the aim of helping patients derive maximum survival benefit from this intensified approach.关键词
转移性结直肠癌/TRIPLETE研究/mFOLFOXIRI/抗表皮生长因子受体治疗Key words
metastatic colorectal cancer/TRIPLETE study/mFOLFOXIRI/anti-epidermal growth factor receptor therapy引用本文复制引用
程怡,吴泽华,骆玉婷,胡华斌,张剑威,邓艳红..从TRIPLETE研究再看左半RAS/BRAF野生型转移性结直肠癌一线治疗的强化策略[J].实用肿瘤杂志,2026,41(3):220-225,6.
